Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Income: 2016-2025

Historic Operating Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.2 million.

  • Rocket Pharmaceuticals' Operating Income rose 24.74% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 8.51%. This contributed to the annual value of -$273.2 million for FY2024, which is 5.22% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Operating Income stood at -$52.2 million for Q3 2025, which was up 26.57% from -$71.1 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Operating Income's 5-year high stood at -$34.0 million during Q2 2021, with a 5-year trough of -$73.7 million in Q2 2024.
  • For the 3-year period, Rocket Pharmaceuticals' Operating Income averaged around -$65.5 million, with its median value being -$65.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Rocket Pharmaceuticals' Operating Income was 25.16% (2021), while the steepest drop was 81.28% (2021).
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Operating Income stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then grew by 8.40% to -$63.3 million in 2023, then increased by 0.92% to -$62.7 million in 2024, then grew by 24.74% to -$52.2 million in 2025.
  • Its Operating Income stands at -$52.2 million for Q3 2025, versus -$71.1 million for Q2 2025 and -$64.4 million for Q1 2025.